Common Blood Thinners Cut Major Risks by 69% in AF Trial

Imagine preventing a stroke with a small, twice-daily pill. That is the provocative hint from SINGLE-AF, a randomized trial that tested modern blood thinners in people with atrial fibrillation who fall into the clinical gray zone for stroke risk.

Atrial fibrillation makes the heart flicker in an irregular rhythm. Blood can pool. Clots can form. One wandering clot can shut down a brain artery and change a life in an instant. Doctors use risk scores to decide who should be offered anticoagulation. But what about the patients who sit just below the high-risk cut-off? Until now, randomized evidence was lacking.

SINGLE-AF enrolled 1,803 patients at 18 centers in South Korea, all judged to have an intermediate stroke risk by CHA2DS2-VASc (a score of 1 for men or 2 for women). Participants were randomly assigned to no anticoagulation or to a direct oral anticoagulant: apixaban 5 mg twice daily or rivaroxaban 20 mg once daily. The trial ran for two years, and the primary endpoint combined stroke, systemic embolism, major bleeding, and cardiovascular death.

The headline finding was striking. Over 24 months the composite outcome occurred in 0.5 percent of those taking a DOAC versus 1.5 percent of patients not anticoagulated. Statistically, that translates to a hazard ratio of 0.31 (95 percent confidence interval 0.10 to 0.94; p = 0.028). Put another way, the relative reduction was roughly 69 percent, with an absolute reduction of about one percentage point.

DOAC therapy was linked to far fewer ischemic strokes without a rise in major bleeding.

Ischemic stroke appeared to drive most of the benefit: 0.1 percent in the DOAC group versus 1.1 percent among those without anticoagulation. Major bleeding remained rare and did not increase on treatment, occurring in 0.3 percent of DOAC recipients versus 0.5 percent of the no-anticoagulation group. Those safety numbers matter as much as the efficacy signal; they are the reason this question has been so contentious for years.

The findings were revealed during a Hot Line session at ESC Congress 2026 and were concurrently published in the New England Journal of Medicine. The trial team, led by Professor Boyoung Joung, framed SINGLE-AF as the first randomized test of modern direct oral anticoagulants in this intermediate-risk population, a cohort previously guided mainly by observational studies and expert judgment.

Why does this change the conversation? Because many clinicians have faced a familiar dilemma: recommend anticoagulation and risk bleeding, or withhold it and accept a small stroke risk. The new randomized data tilt the balance by showing that DOACs can reduce serious thrombotic events with no detectable increase in major hemorrhage over two years. That combination is compelling for patients who have been floating in therapeutic uncertainty.

Of course, one trial does not settle every case. The study population was drawn from Korea, and treatment choices, comorbidities, and bleeding risks vary worldwide. The absolute risk differences were small, meaning individual decisions still require careful discussion about values and preferences. Guideline committees will want to weigh these results alongside other evidence before changing global recommendations and reimbursement policies.

For clinicians and patients, SINGLE-AF offers a new data point: in people with AF and intermediate stroke risk, modern DOACs substantially reduced a composite of stroke, embolism, major bleeding, and cardiovascular death over two years, driven mainly by fewer ischemic strokes. Will this nudge guideline panels and insurers to broaden indications? That is the next chapter, and it will unfold in boardrooms and clinical consultations alike.